NASDAQ: MGNXMacrogenics Inc Stock
$3.78+0.11 (+3%)
Updated Jul 30, 2026
MGNX Price
$3.78
Fair Value Price
N/A
Market Cap
$240.27M
52 Week Low
$1.29
52 Week High
$5.08
P/E
-3.44x
P/B
11.33x
P/S
1.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$157.08M
Earnings
-$70.36M
Gross Margin
74.4%
Operating Margin
-36.75%
Profit Margin
-44.8%
Debt to Equity
9.28
Operating Cash Flow
-$70M
Beta
1.47
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MGNX Overview
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MGNX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MGNX
Ranked#132 of 462
Ranked#132 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $258.38 | A | |
| $11.06 | A | |
| $8.42 | A |
Be the first to know about important MGNX news, forecast changes, insider trades & much more!
MGNX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MGNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGNX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MGNX is poor value based on its book value relative to its share price (11.33x), compared to the US Biotechnology industry average (5.4x)
P/B vs Industry Valuation
MGNX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MGNX due diligence checks available for Premium users.
Valuation
MGNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.44x
Industry
20.57x
Market
17.04x
MGNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.33x
Industry
5.4x
MGNX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGNX's financial health
Profit margin
Revenue
$20.8M
Net Income
-$36.8M
Profit Margin
-177%
MGNX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MGNX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$217.9M
Liabilities
$196.7M
Debt to equity
9.28
MGNX's short-term assets ($182.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGNX's short-term assets ($182.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGNX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MGNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$35.8M
Investing
$45.3M
Financing
-$207.0k
MGNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGNX vs Biotech Stocks
Macrogenics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.